Comorbid ADHD More Prevalent in Boys, Adolescents With Autism Spectrum Disorder
A retrospective study was conducted to evaluate the demographic predictors of ADHD in hospitalized children with ASD and the impact of comorbidities on length of stay.
Attention-Deficit/Hyperactivity Disorder
Novel Stimulant Effective for Adult ADHD, Regardless of Prior Stimulant Exposure
SHP465 mixed amphetamine salts reduced symptoms of attention-deficit/hyperactivity disorder in adults, independent of ADHD treatment history.
Investigational Stimulant Found Effective, Safe for Treatment of ADHD Symptoms in Adults
Investigators conducted a randomized clinical trial to assess the safety and efficacy of the investigational stimulant AR19 for the treatment of symptoms of attention-deficit/hyperactivity disorder in adults.
Insomnia and Alcohol Consumption Linked to ADHD Symptoms
Among adults without a clinical diagnosis of ADHD, heavy alcohol use predicted more severe ADHD symptoms.
Stigmas Identified in Nurse Practitioners’ Attitudes Toward Managing Mental Health Conditions
Researchers conducted a cross-sectional study to assess nurse practitioners’ attitudes and beliefs regarding working with individuals with a mental health disorder.
Study Supports Using WURS and ASRS Jointly to Assess Adult ADHD
In this study, researchers sought to investigate the psychometric properties of the ASRS and WURS in a well-characterized sample of adult ADHD patients and population controls.
FDA: Guidance on Digital Therapeutics for Psychiatric Disorders During COVID-19
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.
Viloxazine NDA Submitted for Review as Potential New ADHD Treatment
The New Drug Application (NDA) for viloxazine hydrochloride (SPN-812; Supernus Pharmaceuticals), a serotonin norepinephrine modulating agent, has been submitted to the Food and Drug Administration (FDA) for the treatment of pediatric patients with attention deficit hyperactivity disorder (ADHD).
Pre-Existing Mental Health Vulnerabilities Associated With Being Bullied
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
First Prescription Device Approved to Treat ADHD
The FDA has permitted for marketing the first medical device indicated for the treatment of attention deficit hyperactivity disorder ADHD.
-
Loading...
-
Loading...
Next post in ADHD Information Center
